Literature DB >> 30729493

Epidemiology, outcome, targeted agents and immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma.

Monika L Metzger1, Christine Mauz-Körholz2.   

Abstract

The epidemiology, outcome and targeted immunotherapy in adolescent and young adult non-Hodgkin and Hodgkin lymphoma were discussed during the 6th International Symposium on Childhood, Adolescent and Young Adult Non-Hodgkin Lymphoma September 26th-29th 2018 in Rotterdam, the Netherlands. This review summarizes some of those presentations, as well as other current and novel antibody therapy, immune check-point inhibitors, chimeric antigen receptor T cells, cancer vaccines and cytotoxic T lymphocyte therapy.
© 2019 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  Hodgkin lymphoma; antibody therapy; cellular immunotherapy; chimeric antigen receptor; non-Hodgkin lymphoma; vaccine therapy

Mesh：

Substances：

Year:  2019        PMID： 30729493     DOI： 10.1111/bjh.15789

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  8 in total

1.  Incidence and survival trends in patients with primary tonsillar lymphoma: a large population-based study.

Authors:  Yan Liang; Haidong Zhang; Yonghong Wu; Min Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-04-09       Impact factor: 2.503

Review 2.  Secondary Dysgammaglobulinemia in Children with Hematological Malignancies Treated with Targeted Therapies.

Authors:  Athanasios Tragiannidis; Andreas H Groll
Journal:  Paediatr Drugs       Date:  2021-07-22       Impact factor: 3.022

3.  Clinical and cytopathological characteristics of HTLV-1+ hodgkin lymphoma.

Authors:  Katsumi Kobata; Shoichi Kimura; Yasuhito Mihashi; Hiromi Iwasaki; Shuichi Nonaka; Shinji Matsumoto; Yasushi Takamatsu; Ilseung Choi; Shigeto Kawauchi; Kenji Ishitsuka; Morishige Takeshita
Journal:  Cancer Med       Date:  2020-06-28       Impact factor: 4.452

4.  Detection of Subclinical Cardiovascular Disease by Cardiovascular Magnetic Resonance in Lymphoma Survivors.

Authors:  Nikki van der Velde; Cécile P M Janus; Daniel J Bowen; H Carlijne Hassing; Isabella Kardys; Flora E van Leeuwen; Cynthia So-Osman; Remi A Nout; Olivier C Manintveld; Alexander Hirsch
Journal:  JACC CardioOncol       Date:  2021-12-21

5.  Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis.

Authors:  Junjie Huang; Wing Sze Pang; Veeleah Lok; Lin Zhang; Don Eliseo Lucero-Prisno; Wanghong Xu; Zhi-Jie Zheng; Edmar Elcarte; Mellissa Withers; Martin C S Wong
Journal:  J Hematol Oncol       Date:  2022-05-11       Impact factor: 23.168

6.  LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.

Authors:  Scott Moerdler; Michelle Ewart; Debra L Friedman; Kara Kelly; Qinglin Pei; Mou Peng; XingXing Zang; Peter D Cole
Journal:  Leuk Lymphoma       Date:  2020-10-28

Review 7.  The Possibilities of Immunotherapy for Children with Primary Immunodeficiencies Associated with Cancers.

Authors:  Frederic Baleydier; Fanette Bernard; Marc Ansari
Journal:  Biomolecules       Date:  2020-07-28

Review 8.  Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.

Authors:  Clifford M Csizmar; Stephen M Ansell
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.